337 related articles for article (PubMed ID: 30520543)
1. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
[TBL] [Abstract][Full Text] [Related]
2. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
[TBL] [Abstract][Full Text] [Related]
3. STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
Conde de la Rosa L; Garcia-Ruiz C; Vallejo C; Baulies A; Nuñez S; Monte MJ; Marin JJG; Baila-Rueda L; Cenarro A; Civeira F; Fuster J; Garcia-Valdecasas JC; Ferrer J; Karin M; Ribas V; Fernandez-Checa JC
J Hepatol; 2021 Jun; 74(6):1429-1441. PubMed ID: 33515644
[TBL] [Abstract][Full Text] [Related]
4. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.
Ma HY; Yamamoto G; Xu J; Liu X; Karin D; Kim JY; Alexandrov LB; Koyama Y; Nishio T; Benner C; Heinz S; Rosenthal SB; Liang S; Sun M; Karin G; Zhao P; Brodt P; Mckillop IH; Quehenberger O; Dennis E; Saltiel A; Tsukamoto H; Gao B; Karin M; Brenner DA; Kisseleva T
J Hepatol; 2020 May; 72(5):946-959. PubMed ID: 31899206
[TBL] [Abstract][Full Text] [Related]
5. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
6. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
[TBL] [Abstract][Full Text] [Related]
7. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.
Kumar S; Verma AK; Rani R; Sharma A; Wang J; Shah SA; Behari J; Salazar Gonzalez R; Kohli R; Gandhi CR
Hepatology; 2020 Nov; 72(5):1586-1604. PubMed ID: 32031683
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
[No Abstract] [Full Text] [Related]
10. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic steatohepatitis-associated hepatocarcinogenesis in mice fed a modified choline-deficient, methionine-lowered, L-amino acid-defined diet and the role of signal changes.
Suzuki-Kemuriyama N; Abe A; Nakane S; Yuki M; Miyajima K; Nakae D
PLoS One; 2023; 18(8):e0287657. PubMed ID: 37535625
[TBL] [Abstract][Full Text] [Related]
12. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
13. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.
Watanabe S; Horie Y; Kataoka E; Sato W; Dohmen T; Ohshima S; Goto T; Suzuki A
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S96-S100. PubMed ID: 17567478
[TBL] [Abstract][Full Text] [Related]
15. Toll-like Receptor 4 on Macrophage Promotes the Development of Steatohepatitis-related Hepatocellular Carcinoma in Mice.
Miura K; Ishioka M; Minami S; Horie Y; Ohshima S; Goto T; Ohnishi H
J Biol Chem; 2016 May; 291(22):11504-17. PubMed ID: 27022031
[TBL] [Abstract][Full Text] [Related]
16. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
17. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
18. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
Liu CH; Chan KM; Chiang T; Liu JY; Chern GG; Hsu FF; Wu YH; Liu YC; Chen Y
Mol Pharm; 2016 Jul; 13(7):2253-62. PubMed ID: 27224003
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease.
Lefere S; Van de Velde F; Hoorens A; Raevens S; Van Campenhout S; Vandierendonck A; Neyt S; Vandeghinste B; Vanhove C; Debbaut C; Verhelst X; Van Dorpe J; Van Steenkiste C; Casteleyn C; Lapauw B; Van Vlierberghe H; Geerts A; Devisscher L
Hepatology; 2019 Mar; 69(3):1087-1104. PubMed ID: 30259536
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.
Sun X; Seidman JS; Zhao P; Troutman TD; Spann NJ; Que X; Zhou F; Liao Z; Pasillas M; Yang X; Magida JA; Kisseleva T; Brenner DA; Downes M; Evans RM; Saltiel AR; Tsimikas S; Glass CK; Witztum JL
Cell Metab; 2020 Jan; 31(1):189-206.e8. PubMed ID: 31761566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
